Research groups All groups >>

Primary Dyslipidemias Group, Miguel Servet University Hospital, IACS, Zaragoza. The group, composed of doctors, chemists, biochemists and nutritionists, has three research components:

1. Lipids Unit. Reference unit for the Zaragoza community that cares for patients with primary disorders of lipid metabolism, particularly focused on subjects with a family histoy of hypercholesterolemia. The unit attends 2,500 patients each year and conducts an exhaustive study of risk factors, lipid metabolism, carotid and femoral echography for the detection of subclinical arteriosclerosis, echographic detection of tendinous xanthomas, and body composition. The Unit participates in many clinical trials, mainly Phase II and III trials of new hypolipemiant drugs.
2. Biobank of Clinical Samples. The available biological samples are serum, plasma and DNA of some 4000 subjects affected with various diseases related to lipid metabolism. Most of the samples are collected from the Lipids Unit and are used for the group's basic research and for collaborations with other related groups.
3. Molecular Research Laboratory. Translational research related to lipid metabolism and cardiovascular risk is conducted at this laboratory in Miguel Servet University Hospital, using a variety of genotyping, proteomic and metabolomic techniques.

Major Lipids Group Research Lines:

• Genetic bases of dominant autosomic hyperlipemias. The objective is to identify new loci responsible for primary forms of hyperlipidemia not dependent on the LDLR gene.
• Relationships between the phenotype and genotype of primary dyslipidemias. The objective is to identify the genetic and environmental factors that modify cardiovascular disease and the lipid phenotype of primary dyslipidemias.

Latest publications

• de Gonzalo-Calvo D, Cenarro A, Martínez-Bujidos M, Badimon L, Bayés-Genís A, Ordonez-Llanos J, Civeira F, Llorente-Cortés V Circulating soluble low-density lipoprotein receptor-related protein 1 (sLRP1) concentration is associated with hypercholesterolemia: A new potential biomarker for atherosclerosis. Int. J. Cardiol. 2015; 201: 20-9

  View abstract

• Ledesma M, Hurtado-Roca Y, León M, Giraldo P, Pocoví M, Civeira F, Guallar E, Ordovas JM, Casasnovas JA, Laclaustra M Association of ferritin elevation and metabolic syndrome in males. Results from the Aragon Workers' Health Study (AWHS). J. Clin. Endocrinol. Metab. 2015; 100: 2081-9

  View abstract

• Saravia G, Civeira F, Hurtado-Roca Y, Andrés E, León M, Pocoví M, Ordovas J, Guallar E, Fernández-Ortiz A, Casasnovas JA, Laclaustra M Glycated Hemoglobin, Fasting Insulin and the Metabolic Syndrome in Males. Cross-Sectional Analyses of the Aragon Workers' Health Study Baseline. PLoS ONE 2015; 10: e0132244

  View abstract

• Baila-Rueda L, Mateo-Gallego R, Perez-Calahorra S, Lamiquiz-Moneo I, De Castro-Orós I, Cenarro A, Civeira F Effect of different fat-enriched meats on non-cholesterol sterols and oxysterols as markers of cholesterol metabolism: Results of a randomized and cross-over clinical trial. Nutr Metab Cardiovasc Dis 2015; 25: 853-9

  View abstract

• Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, Blom D, Civeira F, Krempf M, Lorenzato C, Zhao J, Pordy R, Baccara-Dinet MT, Gipe DA, Geiger MJ, Farnier M ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur. Heart J. 2015; 36: 2996-3003

  View abstract

• Sotos-Prieto M, Moreno-Franco B, Ordovas JM, León M, Casasnovas JA, Peñalvo JL Design and development of an instrument to measure overall lifestyle habits for epidemiological research: the Mediterranean Lifestyle (MEDLIFE) index. Public Health Nutr 2015; 18: 959-67

  View abstract

• Ascaso JF, Mata P, Arbona C, Civeira F, Valdivielso P, Masana L [Homozygous familial hypercholesterolaemia: Spanish adaptation of the position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Consensus document of the Spanish Society of Arteriosclerosis (SEA) and Familial Hypercholesterolaemia Foundation (FHF)]. Clin Investig Arterioscler 2015; 27: 80-96

  View abstract

• Guardiola M, Cofán M, De Castro-Orós I, Cenarro A, Plana N, Talmud PJ, Masana L, Ros E, Civeira F, Ribalta J APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis. Atherosclerosis 2015; 240: 98-104

  View abstract

• Versmissen J, Oosterveer DM, Yazdanpanah M, Dehghan A, Hólm H, Erdman J, Aulchenko YS, Thorleifsson G, Schunkert H, Huijgen R, Vongpromek R, Uitterlinden AG, Defesche JC, van Duijn CM, Mulder M, Dadd T, Karlsson HD, Ordovas J, Kindt I, Jarman A, Hofman A, van Vark-van der Zee L, Blommesteijn-Touw AC, Kwekkeboom J, Liem AH, van der Ouderaa FJ, Calandra S, Bertolini S, Averna M, Langslet G, Ose L, Ros E, Almagro F, de Leeuw PW, Civeira F, Masana L, Pinto X, Simoons ML, Schinkel AF, Green MR, Zwinderman AH, Johnson KJ, Schaefer A, Neil A, Witteman JC, Humphries SE, Kastelein JJ, Sijbrands EJ Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach. Eur. J. Hum. Genet. 2015; 23: 381-7

  View abstract

• Mateo-Gallego R, Baila-Rueda L, Mouratidou T, De Castro-Orós I, Bea AM, Perez-Calahorra S, Cenarro A, Moreno LA, Civeira F Serum plant sterols as surrogate markers of dietary compliance in familial dyslipidemias. Clin Nutr 2015; 34: 490-5

  View abstract

All publications